Intellia Therapeutics, Inc.
NTLA
$11.91
$0.080.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 16.71% | 24.97% | 20.49% | 14.64% | 5.62% |
| Total Depreciation and Amortization | 50.16% | 52.15% | 54.82% | 22.47% | 2.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.96% | -56.35% | -48.78% | -33.37% | -13.34% |
| Change in Net Operating Assets | 57.84% | -203.47% | -720.91% | -657.66% | -524.05% |
| Cash from Operations | 17.19% | 3.71% | -13.14% | -15.11% | -12.14% |
| Capital Expenditure | 36.83% | 88.20% | 80.46% | 68.59% | 65.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -113.35% | -8.03% | 74.47% | 1,248.34% | 198.94% |
| Cash from Investing | -114.05% | -6.53% | 81.60% | 1,665.52% | 222.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 249.45% | 31.25% | -29.21% | -54.53% | -56.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 249.45% | 31.25% | -29.21% | -54.53% | -56.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -289.29% | 105.12% | 6.25% | 256.22% | 165.31% |